Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical
Treament related mortality · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy with alemtuzumab showed no clear difference in treament related mortality compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (low certainty).
1 finding from 1 review
- RR 3.2 [0.66, 15.5]2 studies · 177 participantsLow